National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, said that in conjunction with an equity investment in Resilience from Mubadala Investment Company PJSC, an Abu Dhabi sovereign investor, that the two parties have signed a deal intended to help secure the global biopharma supply chain and advance the United Arab Emirates’ (UAE) life sciences ecosystem through a biopharma manufacturing collaboration—which would result in the construction of a new, state-of-the-art manufacturing facility in Abu Dhabi, UAE.

Under the agreement, Mubadala will establish the new manufacturing facility, which will be operated by Resilience, to manufacture certain biopharmaceutical-related products in the UAE. The facility will include a range of therapeutics for complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders, as well as vaccines.

As part of the collaboration, Resilience has agreed to provide manufacturing, technology, and operational expertise for the Abu Dhabi-based facility and integrate the site as a node within its global network. The facility would be the first Good Manufacturing Practice (GMP) biopharma facility in the region based in Abu Dhabi to manufacture essential life sciences products for advanced biologics.

“We are excited to expand the footprint of our Resilience manufacturing network outside of North America. This is a significant milestone, not just for our company but also for our nation,” said Rahul Singhvi, CEO of Resilience. “We look forward to working alongside America’s allies in the region to ensure that trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local, regional, and global economies.”

Badr Al-Olama, executive director, UAE clusters at Mubadala, said, “We are actively investing in innovation and firmly believe that, by strengthening Abu Dhabi’s national life sciences ecosystem, we are building a future focused, sustainable and knowledge-based economy for the UAE. Through this agreement, Mubadala and its group companies will unlock further opportunities for growth within the life sciences ecosystem, and alongside our key partners, will play an instrumental role in establishing a state-of-the-art biopharma campus that will secure the region’s supply chain from Abu Dhabi.”